Clinical Trials Logo
  1. Home
  2. Premature Infants
  3. NCT01077271

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

Premature Infants Clinical Trial

Official title:
PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA Over 3 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria

Clinical Trial Summary

Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against respiratory syncytial virus (RSV) infection as shown in the IMpact study. Many factors such as parents' knowledge of burden of respiratory syncytial virus disease or physicians' satisfaction with Synagis as well as the appropriate use of the product might influence compliance. The primary objective of this observational study is to evaluate the compliance to Synagis under daily pediatricians practice conditions in premature infants 33 to 35 weeks gestational age (wGA). Palivizumab, monoclonal antibody for passive immunoprophylaxis against severe respiratory syncytial virus disease, was administered according to usual clinical practice. Compliance was assessed using four criteria: The number of injections per participant per respiratory syncytial virus season, the body site where injections were administered, the interval in days between injections, and the dosage per administration. Originally the study was to include two respiratory syncytial virus seasons but was extended to a third season.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01077271
Study type Observational
Source Abbott
Contact
Status Completed
Phase N/A
Start date October 2008
Completion date May 2011
View Details
See also
  Status Clinical Trial Phase
Completed NCT02785926 - Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates
Completed NCT01946971 - Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER) Phase 1/Phase 2
Completed NCT01530360 - Cerebral Oxygenation to Guide Medical Interventions in Extremely Preterm Infants Phase 1
Completed NCT00681018 - Feeding Study in Premature Infants N/A
Completed NCT00217191 - Ibuprofen and Renal Function in Premature Infants Phase 4
Completed NCT00282113 - Effects of Probiotic and Prebiotic Combinations on Premature Infants N/A
Active, not recruiting NCT02943746 - Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants N/A
Completed NCT01994954 - A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants N/A
Completed NCT00389909 - Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants Phase 4
Completed NCT00747591 - Urine Concentration of S100B in Extremely Premature Infants N/A
Recruiting NCT04555590 - Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants N/A
Completed NCT06352047 - The Effects of Positioning After Extubation of Preterm Infants on the Respiratory Functions N/A
Completed NCT03217045 - Nutrition Protocol and Premature Infants' Growth
Recruiting NCT03552952 - Development of Preterm Infant Gut Microbiome
Recruiting NCT06332521 - Infant Crying, a Bioacoustic Prognostic Signal for Neurodevelopment
Completed NCT04659083 - How NAVA Works in Preterm Infants With Irregular Respiratory Efforts
Completed NCT05807191 - The Effect of Using Clinical Guidelines on Kangaroo Care on Newborn and Maternal Outcomes N/A
Completed NCT03914690 - Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage Phase 2
Completed NCT01140243 - Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital N/A
Completed NCT00957840 - Intraventricular Hemorrhage and Post Hemorrhagic Ventricular Dilation: Natural Course, Treatment, and Outcome N/A